Entyvio 300 MG vials
Ended Awarded
- Contract number
- SPE2DB25FL1W4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $98,899
Award facts
- Contract value 100% obligated
- $98,898.60 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a firm fixed-price delivery order valued at $98.9M by the Defense Logistics Agency (DLA) for the supply of Entyvio 300 mg vials. This delivery order, issued on September 2, 2025, with an ultimate completion date of September 23, 2025, represents a specific product fulfillment under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA. The award carries no set-aside designation, allowing the company to compete directly in federal procurement markets based on its established capabilities as a woman-owned small business. The place of performance is Park Ridge, Illinois, where the company maintains its primary operations.
This delivery order falls under DMS Pharmaceutical Group's significant single-award IDC with the DLA valued at $499.999B and valid through November 2026, which enables the agency to issue firm fixed-price orders for pharmaceutical products supporting military health facilities worldwide. Entyvio (vedolizumab), a biologic medication used in the treatment of inflammatory bowel disease, reflects the company's established portfolio of specialty pharmaceutical products delivered to Department of Defense healthcare sites. The company's robust federal contract history demonstrates consistent success in securing pharmaceutical supply contracts with the DLA across diverse product categories including biologics, prescription medications, and medical consumables, positioning it as a critical supplier within the federal pharmaceutical supply chain.
Quick answers
Who was awarded contract SPE2DB25FL1W4?
SPE2DB25FL1W4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 2, 2025.
How much is contract SPE2DB25FL1W4 worth?
The government has obligated $98,899 on SPE2DB25FL1W4.
Is contract SPE2DB25FL1W4 an order under another contract?
Yes. SPE2DB25FL1W4 is a delivery order under SPE2DB20D9331, an indefinite delivery contract.
Was contract SPE2DB25FL1W4 competed?
The extent of competition for SPE2DB25FL1W4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award